Inflammatory Mediators and Angiogenic Factors in Choroidal Neovascularization: Pathogenetic Interactions and Therapeutic Implications

被引:70
作者
Campa, Claudio [1 ,2 ]
Costagliola, Ciro [3 ]
Incorvaia, Carlo [1 ]
Sheridan, Carl [2 ]
Semeraro, Francesco [4 ]
De Nadai, Katia [1 ,5 ]
Sebastiani, Adolfo [1 ]
Parmeggiani, Francesco [1 ]
机构
[1] Univ Ferrara, Dept Ophthalmol, I-44121 Ferrara, Italy
[2] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England
[3] Univ Molise, Dept Hlth Sci, Campobasso, Italy
[4] Univ Brescia, Dept Ophthalmol, Brescia, Italy
[5] Camposampiero Hosp, Ctr Retinitis Pigmentosa Veneto Reg, Camposampiero, Italy
关键词
ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT-FACTOR-H; RETINAL-PIGMENT EPITHELIUM; INTRAVITREAL BEVACIZUMAB AVASTIN; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; MATRIX METALLOPROTEINASES; RANIBIZUMAB LUCENTIS; LOC387715; GENOTYPES; GENE POLYMORPHISMS;
D O I
10.1155/2010/546826
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Choroidal neovascularization (CNV) is a common and severe complication in heterogeneous diseases affecting the posterior segment of the eye, the most frequent being represented by age-related macular degeneration. Although the term may suggest just a vascular pathological condition, CNV is more properly definable as an aberrant tissue invasion of endothelial and inflammatory cells, in which both angiogenesis and inflammation are involved. Experimental and clinical evidences show that vascular endothelial growth factor is a key signal in promoting angiogenesis. However, many other molecules, distinctive of the inflammatory response, act as neovascular activators in CNV. These include fibroblast growth factor, transforming growth factor, tumor necrosis factor, interleukins, and complement. This paper reviews the role of inflammatory mediators and angiogenic factors in the development of CNV, proposing pathogenetic assumptions of mutual interaction. As an extension of this concept, new therapeutic approaches geared to have an effect on both the vascular and the extravascular components of CNV are discussed.
引用
收藏
页数:14
相关论文
共 158 条
[1]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[2]   A prospective study on intravitreal bevacizumab (Avastin®) for neovascular age-related macular degeneration of different durations [J].
Algvere, Peep V. ;
Steen, Bjoern ;
Seregard, Stefan ;
Kvanta, Anders .
ACTA OPHTHALMOLOGICA, 2008, 86 (05) :482-489
[3]   Lymphangiogenesis in development and human disease [J].
Alitalo, K ;
Tammela, T ;
Petrova, TV .
NATURE, 2005, 438 (7070) :946-953
[4]  
AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
[5]   Blockade of nitric-oxide synthase reduces choroidal neovascularization [J].
Ando, A ;
Yang, A ;
Nambu, H ;
Campochiaro, PA .
MOLECULAR PHARMACOLOGY, 2002, 62 (03) :539-544
[6]   Macrophages inhibit neovascularization in a murine model of age-related macular degeneration [J].
Apte, Rajendra S. ;
Richter, Jennifer ;
Herndon, John ;
Ferguson, Thomas A. .
PLOS MEDICINE, 2006, 3 (08) :1371-1381
[7]  
Arnold J, 2001, AM J OPHTHALMOL, V131, P541
[8]   VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells [J].
Asahara, T ;
Takahashi, T ;
Masuda, H ;
Kalka, C ;
Chen, DH ;
Iwaguro, H ;
Inai, Y ;
Silver, M ;
Isner, JM .
EMBO JOURNAL, 1999, 18 (14) :3964-3972
[9]   Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration [J].
Avery, RL ;
Pieramici, DJ ;
Rabena, MD ;
Castellarin, AA ;
Nasir, MA ;
Giust, MJ .
OPHTHALMOLOGY, 2006, 113 (03) :363-372
[10]   Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 [J].
Barleon, B ;
Sozzani, S ;
Zhou, D ;
Weich, HA ;
Mantovani, A ;
Marme, D .
BLOOD, 1996, 87 (08) :3336-3343